Cardiovascular disease: A target for the pharmacological effects of quercetin

Current Topics in Medicinal Chemistry

Volumn 15, Issue 17, 2015, Pages 1735-1742

  Gormaz, Juan Guillermo ^a   Quintremil, Sebastián ^a   Rodrigo, Ramón ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Bioavailability; Cardiovascular diseases; Flavonols; Quercetin

Indexed keywords

QUERCETIN; ANTIOXIDANT;

ARTICLE; ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISORDERS OF CHOLESTEROL METABOLISM; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; NONHUMAN; PHARMACODYNAMICS; REPERFUSION INJURY; SIGNAL TRANSDUCTION; THORAX INJURY; CARDIOVASCULAR DISEASES; CHEMICAL STRUCTURE; CHEMISTRY;

ANTIOXIDANTS; CARDIOVASCULAR DISEASES; HUMANS; MOLECULAR STRUCTURE; QUERCETIN;

EID: 84931834215     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150427124357     Document Type: Article

References (96)

1. Larson, A. J.; Symons, J. D.; Jalili T. Therapeutic potential of quercetin to decrease blood pressure: review of efficacy and mechanisms. Adv. Nutr., 2012, 3, 39-46.
2. Pallauf, K.; Giller, K.; Huebbe, P.; Rimbach, G. Nutrition and healthy ageing: calorie restriction or polyphenol-rich "MediterrAsian" diet? Oxid. Med. Cell Longev., 2013, 2013, 707421.
3. Ross, J. A.; Kasum, C. M. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr., 2002, 22, 19-34.
4. Ross, R. W, Victor R. Polyphenols in Human Health and Disease, 1er ed.; Elsevier: Amsterdam, 2014
5. Hakkinen, S. H.; Karenlampi, S. O.; Heinonen I. M.;Mykkanen, H. M.; Torronen, A. R. Content of the flavonolsquercetin, myricetin, and kaempferol in 25 edible berries. J. Agric. Food. Chem., 1999, 47, 2274-2279.
6. Wiczkowski, W.; Romaszko, J.; Bucinski, A.; Szawara-Nowak, D.; Honke, J.; Zielinski, H.; Piskula, M. K.Quercetin from shallots (Allium cepa L. var. aggregatum) is more bioavailable than its glucosides. J. Nutr., 2008, 138, 885-888.
7. Nemeth, K.; Piskula, M. K. Food content, processing, absorption and metabolism of onion flavonoids. Crit. Rev. Food. Sci. Nutr., 2007, 47,397-409.
8. Kelly, G. S. Quercetin. Monograph. Altern. Med. Rev., 2011, 16, 172-194.
9. USD Database for the flavonoid content of selected foods. Release 3.1 (May 2014). http://www.ars.usda.gov/SP2UserFiles/Place/ 12354500/Data/Flav/Flav_R03-1.pdf [Accessed on August 2, 2014]
10. Perez-Lopez, F. R.; Chedraui, P.; Haya, J.; Cuadros, J. L. Effects of the Mediterranean diet on longevity and age-related morbid conditions. Maturitas., 2009, 64, 67-79.
11. Roman, B.; Carta, L.; Martinez-Gonzalez, M. A.; Serra-Majem, L. Effectiveness of the Mediterranean diet in the elderly. Clin. Interv. Aging., 2008, 3, 97-109.
12. Serra-Majem, L.; Roman, B.; Estruch, R. Scientific evidence of interventions using the Mediterranean diet: a systematic review. Nutr. Rev., 2006, 64, 27-47.
13. Scholz, S.; Williamson, G. Interactions affecting the bioavailability of dietary polyphenols in vivo. Int.J.Vitam.Nutr. Res., 2007, 77, 224-235.
14. Hallmann, E.The influence of organic and conventional cultivation systems on the nutritional value and content of bioactive compounds in selected tomato types. J. Sci. Food. Agric., 2012, 92, 2840-2848.
15. Lee, J.; Mitchell, A. E.Quercetin and isorhamnetin glycosides in onion (Allium cepa L.): varietal comparison, physical distribution, coproduct evaluation, and long-term storage stability. J. Agric. Food. Chem., 2011, 59, 857-863.
16. Zhang, M.; Swarts, S. G.; Yin, L.; Liu, C.; Tian, Y.; Cao, Y.; Swarts, M.; Yang, S.; Zhang, S. B.; Zhang, K.; Ju, S.; Olek, D. J. Jr.; Schwartz, L.; Keng, P. C.; Howell, R.; Zhang, L.; Okunieff, P. Antioxidant properties of quercetin. Adv. Exp. Med. Biol., 2011, 701, 283-289.
17. Nabavi SM.; Nabavi SF., Eslami S.; Moghaddam AH. In vivo protective effects of quercetin against sodium fluoride-induced oxidative stress in the hepatic tissue. Food Chem., 2012, 132, 931- 5.
18. Nabavi SF.; Russo GL.; Daglia M.; Nabavi SM. Role of quercetin as an alternative for obesity treatment: you are what you eat! Food Chem., 2015, 179, 305-10.
19. Adewole, S.O.; Caxton-Martins, E.A.; Ojewole, J.A. Protective effect of quercetin on the morphology of pancreatic beta-cells of streptozotocin-treated diabetic rats. Afr. J. Tradit. Complement Altern. Med., 2006, 4, 64-74.
20. Rogerio, A.P.; Kanashiro, A.; Fontanari, C.; da Silva, E. V.; Lucisano- Valim, Y. M.;Soares, E. G.; Faccioli, L. H. Antiinflammatory activity of quercetin and isoquercitrin in experimental murine allergic asthma. Inflamm. Res., 2007, 56, 402-408.
21. Stefek, M. Natural flavonoids as potential multifunctional agents in prevention of diabetic cataract. Interdiscip Toxicol., 2011, 4, 69-77.
22. Borska, S.; Drag-Zalesinska, M.; Wysocka, T.; Sopel, M.; Dumanska, M.; Zabel, M.; Dziegiel, P.Antiproliferative and pro-apoptotic effects of quercetin on human pancreatic carcinoma cell lines EPP85-181P and EPP85-181RDB. Folia. Histochem. Cytobiol., 2010, 48, 222-229.
23. Chuang, C. C.; Martinez, K.; Xie, G,; Kennedy, A.; Bumrungpert, A.; Overman, A.; Jia, W.; McIntosh, M. K.Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor- {alpha}-mediated inflammation and insulin resistance in primary human adipocytes. Am. J. Clin. Nutr., 2010, 92, 1511-1521.
24. Ortega, M. G.; Saragusti, A. C.; Cabrera, J. L.; Chiabrando, G. A.Quercetintetraacetyl derivative inhibits LPS-induced nitric oxide synthase (iNOS) expression in J774A.1 cells. Arch. Biochem. Biophys., 2010, 498, 105-110.
25. Chang, H. C.; Yang, Y. R.; Wang, P. S.; Wang, R. Y.Quercetin Enhances Exercise-Mediated Neuroprotective Effects in Brain Ischemic Rats. Med. Sci. Sports. Exerc., 2014, 46, 1908-16.
26. Jin, H. B.; Yang, Y. B.; Song, Y. L.; Zhang, Y. C.; Li, Y. R. Protective roles of quercetin in acute myocardial ischemia and reperfusion injury in rats. Mol. Biol. Rep., 2012, 39, 11005-11009.
27. Chen, Y. W.; Chou, H. C.; Lin, S. T.; Chen, Y. H.; Chang, Y. J.; Chen, L.; Chan, H. L. Cardioprotective Effects of Quercetin in Cardiomyocyte under Ischemia/Reperfusion Injury. Evid.Based Complement Alternat. Med., 2013, 2013, 364519.
28. Liu, H.; Guo, X.; Chu, Y.; Lu, S. Heart protective effects and mechanism of quercetin preconditioning on anti-myocardial ischemia reperfusion (IR) injuries in rats. Gene, 2014, 545, 149-155.
29. Wang, Y.; Zhang, Z. Z.; Wu, Y.; Ke, J. J.; He, X. H.; Wang, Y. L.Quercetinpostconditioning attenuates myocardial ischemia/ reperfusion injury in rats through the PI3K/Akt pathway. Braz. J. Med. Biol. Res., 2013, 46, 861-867.
30. Cevik, O.; Cadırcı, S.; Şener, T. E.; Tinay, I.; Akbal, C.; Tavukcu, H. H.; Cetinel, S.; Kıran, D.; Şener, G.Quercetin treatment against ischemia/reperfusion injury in rat corpus cavernosum tissue: a role on apoptosis and oxidative stress. Free. Radic. Res., 2013, 47, 683- 691.
31. Lapi, D.; Vagnani, S.; Pignataro, G.; Esposito, E.; Paterni, M.; Colantuoni, A., Protective Effects of Quercetin on Rat Pial Microvascular Changes during Transient Bilateral Common Carotid Artery Occlusion and Reperfusion. Front. Physiol., 2012, 3, 32.
32. Panda, S.; Kar, A.; Banerjee, T.; Sharma, N., Combined effects of quercetin and atenolol in reducing isoproterenol-induced cardiotoxicity in rats: possible mediation through scavenging free radicals. Cardiovasc. Toxicol., 2012, 12, 235-242.
33. Li, M.; Jiang, Y.; Jing, W.; Sun, B.; Miao, C.; Ren, L.Quercetin provides greater cardioprotective effect than its glycoside derivative rutin on isoproterenol-induced cardiac fibrosis in the rat. Can. J. Physiol. Pharmacol., 2013, 91, 951-959.
34. Punithavathi, V. R.; StanelyMainzen Prince, P. The cardioprotective effects of a combination of quercetin and α-tocopherol on isoproterenol- induced myocardial infarcted rats. J. Biochem. Mol. Toxicol., 2011, 25, 28-40.
35. Chen, J.Y.; Hu, R. Y.; Chou, H. C.Quercetin-induced cardioprotection against doxorubicin cytotoxicity. J. Biomed. Sci., 2013, 20, 95.
36. Riha, M.; Vopršalova, M.; Pilařova, V.; Semecky, V.; Holečkova, M.; Vavrova, J.; Palicka, V.; Filipsky, T.; Hrdina, R.; Novakova, L.; Mladěnka, P., Oral administration of quercetin is unable to protect against isoproterenol cardiotoxicity. Naunyn. Schmiedebergs Arch. Pharmacol., 2014, 387, 823-835.
37. Badimon, L.; Vilahur, G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J. Intern. Med., 2014, In press, doi: 10.1111/joim.12296.
38. Lara-Guzman, O. J.; Tabares-Guevara, J. H.; Leon-Varela, Y. M.;, Alvarez, R. M.; Roldan, M.; Sierra, J. A.; Londono-Londono, J. A.; Ramirez-Pineda, J. R.Proatherogenicmacrophageactivities are targeted by the flavonoid quercetin. J. Pharmacol. Exp. Ther., 2012, 343, 296-306.
39. Kawai, Y.; Nishikawa, T.; Shiba, Y.; Saito, S.; Murota, K.; Shibata, N.; Kobayashi, M.; Kanayama, M.; Uchida, K.; Terao, J. Macrophage as a target of querceting lucuronides in human atherosclerotic arteries: implication in the anti-atherosclerotic mechanism of dietary flavonoids. J. Biol. Chem., 2008, 283, 9424-9434.
40. Shen, Y.; Ward, N. C.; Hodgson, J. M.; Puddey, I. B.; Wang, Y., Zhang, D.; Maghzal, G. J.; Stocker, R.; Croft, K. D. Dietary quercetin attenuates oxidant-induced endothelial dysfunction and atherosclerosis in apolipoprotein E knockout mice fed a high-fat diet: a critical role for heme oxygenase-1. Free. Radic. Biol. Med., 2013, 65, 908-915.
41. Bhaskar, S.; Kumar, K. S.; Krishnan, K.; Antony, H.Quercetin alleviates hypercholesterolemic diet induced inflammation during progression and regression of atherosclerosis in rabbits. Nutrition, 2013, 29, 219-229.
42. Nekohashi, M.; Ogawa, M.; Ogihara, T.; Nakazawa, K.; Kato, H.; Misaka, T.; Abe, K.; Kobayashi, S.Luteolin and quercetin affect the cholesterol absorption mediated by epithelial cholesterol transporter niemann-pick c1-like 1 in caco-2 cells and rats. PLoS One, 2014, 9, e97901.
43. Delahaye, F., Should we eat less salt? Arch. Cardiovasc. Dis., 2013, 106, 324-332.
44. Olaleye, M.; Crown, O.; Akinmoladun, A.; Akindahunsi, A.Rutin and quercetin show greater efficacy than nifedipin in ameliorating hemodynamic, redox, and metabolite imbalances in sodium chloride- induced hypertensive rats. Hum. Exp. Toxicol., 2013, 33, 602- 608.
45. Mosawy, S.; Jackson, D. E.; Woodman, O. L.; Linden, M. D., Inhibition of platelet-mediated arterial thrombosis and platelet granule exocytosis by 3',4'-dihydroxyflavonol and quercetin. Platelets, 2013, 24, 594-604.
46. Khandelwal, A. R.; Hebert, V. Y.; Kleinedler, J. J.; Rogers, L. K.; Ullevig, S. L.; Asmis, R.; Shi, R.; Dugas, T. R. Resveratrol and quercetin interact to inhibit neointimal hyperplasia in mice with a carotid injury. J. Nutr., 2012, 142, 1487-1494.
47. Demir, F.; Guzel, A.; Kat, C.; Karadeniz, C.; Akdemir, U.; Okuyucu, A.; Gacar, A.; Ozdemir, S.; Guvenc, T. A combination of methylprednisolone and quercetin is effective for the treatment of cardiac contusion following blunt chest trauma in rats. Braz. J. Med. Biol. Res., 2014, 47,766-772.
48. Gao, C.; Chen, X.; Li, J.; Li, Y.; Tang, Y.; Liu, L.; Chen, S.; Yu, H.; Liu, L.; Yao, P. Myocardial mitochondrial oxidative stress and dysfunction in intense exercise: regulatory effects of quercetin. Eur. J. Appl. Physiol., 2014, 114,695-705.
49. Kleemann, R.; Verschuren, L.; Morrison, M.; Zadelaar, S; van Erk, M. J.; Wielinga, P. Y.; Kooistra, T. Anti-inflammatory, antiproliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis, 2011, 218, 44-52.
50. Keli, S. O.; Hertog, M. G.; Feskens, E. J.; Kromhout, D. Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study. Arch. Intern. Med., 1996, 156, 637-642.
51. Knekt, P.; Jarvinen, R.; Reunanen, A.; Maatela, J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ, 1996, 312, 478-481.
52. Conquer, J. A.; Maiani, G.; Azzini, E.; Raguzzini, A.; Holub, B. J. Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J. Nutr., 1998, 128, 593-597.
53. Loke, W. M.; Hodgson, J. M.; Proudfoot, J. M.; McKinley, A. J.; Puddey, I. B.; Croft, K. D. Pure dietary flavonoids quercetin and (-)-epicatechin augment nitric oxide products and reduce endothelin- 1 acutely in healthy men. Am. J. Clin. Nutr., 2008, 88, 1018-1025.
54. Edwards, R. L.; Lyon, T.; Litwin, S. E.; Rabovsky, A.; Symons, J. D.; Jalili, T., Quercetin reduces blood pressure in hypertensive subjects. J. Nutr., 2007, 137, 2405-2411.
55. Egert, S.; Bosy-Westphal, A.; Seiberl, J.; Kurbitz, C.; Settler, U.; Plachta-Danielzik, S.; Wagner, A. E.; Frank, J.; Schrezenmeir, J.; Rimbach, G.; Wolffram, S.; Muller, M. J.Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled crossover study. Br. J. Nutr., 2009, 102, 1065-1074.
56. Egert, S.; Rimbach, G.; Muller, M. J. No evidence for a thermic effect of the dietary flavonolquercetin: a pilot study in healthy normal-weight women. Eur. J. Appl. Physiol., 2011, 111, 869-873.
57. Hubbard, G. P.; Wolffram, S.; Lovegrove, J. A.; Gibbins, J. M. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J. Thromb. Haemost., 2004, 2, 2138-2145.
58. Malishevskaia, I. V.; Ilashchuk, T. A.; Okipniak, I. V. Therapeutic efficacy of quercetin in patients with is ischemic heart disease with underlying metabolic syndrome. Georgian Med. News, 2013, 225, 67-71.
59. Kaushik, D.; O'Fallon, K.; Clarkson, P. M.; Dunne, C. P.; Conca, K. R.; Michniak-Kohn, B. Comparison of quercetin pharmacokinetics following oral supplementation in humans. J. Food. Sci., 2012, 77, H231-H238.
60. Gugler, R.; Leschik, M.; Dengler, H. J. Disposition of quercetin in man after single oral and intravenous doses. Eur.J. Clin. Pharmacol., 1975, 9, 229-234.
61. Galindo, P.; Gonzalez-Manzano, S.; Zarzuelo, M. J.; Gomez- Guzman, M.; Quintela, A. M.; Gonzalez-Paramas, A.; Santos- Buelga, C.; Perez-Vizcaino, F.; Duarte, J.; Jimenez, R. Different cardiovascular protective effects of quercetin administered orally or intraperitoneally in spontaneously hypertensive rats. Food Funct., 2012, 3: 643-650.
62. Scholz, S.; Williamson, G. Interactions affecting the bioavailability of dietary polyphenols in vivo. Int. J. Vitam. Nutr. Res., 2007, 77, 224-235.
63. Bolling, B. W.; Court, M. H.; Blumberg, J. B.; Chen, C. Y. Microsomal quercetinglucuronidation in rat small intestine depends on age and segment. Drug. Metab. Dispos., 2011, 39: 1406-1414.
64. Galindo, P.; Rodriguez-Gomez, I.; Gonzalez-Manzano, S.; Duenas, M.; Jimenez, R.; Menendez, C.; Vargas, F.; Tamargo, J.; Santos- Buelga, C.; Perez-Vizcaino, F.; Duarte, J. Glucuronidatedquercetinlowersbloodpressure in spontaneously hypertensive rats via deconjugation. PLoS One, 2012, 7, e32673.
65. Lee, J.; Mitchell, A. E. Pharmacokinetics of quercetin absorption from apples and onions in healthy humans. J. Agric. Food. Chem., 2012, 60, 3874-3881.
66. Mukai, R.; Fujikura, Y.; Murota, K.; Uehara, M.; Minekawa, S.; Matsui, N.; Kawamura, T.; Nemoto, H.; Terao, J.Prenylation enhances quercetin uptake and reduces efflux in Caco-2 cells and enhances tissue accumulation in mice fed long-term. J. Nutr., 2013, 143, 1558-1564.
67. Madaan, K.; Lather, V.; Pandita, D. Evaluation of polyamidoaminedendrimers as potential carriers for quercetin, a versatile flavonoid. Drug Deliv., 2014, 20, 1-9.
68. Varshosaz, J.; Jafarian, A.; Salehi, G.; Zolfaghari, B. Comparing different sterol containing solid lipid nanoparticles for targeted delivery of quercetin in hepatocellular carcinoma. J. Liposome Res., 2014, 24, 191-203.
69. Jain, S.; Jain, A. K.; Pohekar, M.; Thanki, K. Novel selfemulsifying formulation of quercetin for improved in vivo antioxidant potential: implications for drug-induced cardiotoxicity and nephrotoxicity. Free. Radic. Biol. Med., 2013, 65, 117-130.
70. Fang, R.; Jing, H.; Chai, Z.; Zhao, G.; Stoll, S.; Ren, F.; Liu, F.; Leng, X. Design and characterization of protein-quercetin bioactive nanoparticles. J. Nanobiotechnol., 2011, 9, 19.
71. Sahoo, N. G.; Kakran, M.; Shaal, L. A.; Li, L.; Muller, R. H.; Pal, M.; Tan, L. P. Preparation and characterization of quercetinnanocrystals. J. Pharm. Sci., 2011, 100, 2379-2390.
72. Kakran, M.; Shegokar, R.; Sahoo, N. G.; Gohla, S.; Li, L.; Muller, R. H. Long-term stability of quercetinnanocrystals prepared by different methods. J. Pharm. Pharmacol., 2012, 64, 1394-1402.
73. Sun, H.; Xu, H.; Yang, X.; Li, N.; Liu, Z.; Pan, W.; Yuan, Y. Formulation of a stable and high-loaded quercetin injectable emulsion. Pharm. Dev. Technol., 2011. 16, 609-615.
74. Weiss-Angeli, V.; Poletto, F. S.; de Marco, S. L.; Salvador, M.; da Silveira, N. P.; Guterres, S. S.; Pohlmann, A. R. Sustainedantioxidantactivity of quercetin-loadedlipid-corenanocapsules. J. Nanosci. Nanotechnol., 2012, 12, 2874-2880.
75. Smith, A. J.; Kavuru, P.; Wojtas, L.; Zaworotko, M. J.; Shytle, R. D.Cocrystals of quercetin with improved solubility and oral bioavailability. Mol. Pharm., 2011, 8, 1867-1876.
76. Guo, Y.; Mah, E.; Davis, C. G.; Jalili, T.; Ferruzzi, M. G.; Chun, O. K.; Bruno, R. S. Dietary fat increases quercetin bioavailability in overweight adults. Mol.Nutr.Food. Res., 2013, 57, 896-905.
77. Matouk, A. I.; Taye, A.; Heeba, G. H.; El-Moselhy, M. A. Quercetin augments the protective effect of losartan against chronic doxorubicin cardiotoxicity in rats. Environ. Toxicol. Pharmacol., 2013, 36, 443-450.
78. Challa, V. R.; Babu, P. R.; Challa, S. R.; Johnson, B.; Maheswari, C. Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. Drug. Dev. Ind. Pharm., 2013, 39, 865-872.
79. Singh, S. P.; Konwar, B. K. Molecular docking studies of quercetin and its analogues against human inducible nitric oxide synthase. Springerplus, 2012, 1, 69.
80. Nabavi S.F.; Nabavi S.M.;Mirzaei M.; Moghaddam. Protective effect of quercetin against sodium fluoride induced oxidative stress in rat's heart. Food Funct., 2012, 3, 437.
81. Lapi, D.; Vagnani, S.; Pignataro, G.; Esposito, E.; Paterni, M.; Colantuoni, A. Rat Pial Microvascular Responses to Transient Bilateral Common Carotid Artery Occlusion and Reperfusion: Quercetin's Mechanism of Action. Front Physiol., 2012, 3, 99.
82. Li, P. G.; Sun, L.; Han, X.; Ling, S.; Gan, W. T.; Xu, J. W.Quercetin induces rapid eNOS phosphorylation and vasodilation by an Akt-independent and PKA-dependent mechanism. Pharmacology, 2012, 89, 220-228.
83. Mahmoud, M. F.; Hassan, N. A.; El Bassossy, H. M.; Fahmy, A. Quercetin protects against diabetes-induced exaggerated vasoconstriction in rats: effect on low grade inflammation. PLoS One, 2013, 8, e63784.
84. Angeloni, C.; Hrelia, S.Quercetin reduces inflammatory responses in LPS-stimulated cardiomyoblasts. Oxid. Med. Cell. Longev., 2012, 2012, 837104.
85. Glaeser, H.; Bujok, K.; Schmidt, I.; Fromm, M. F.; Mandery, K. Organic anion transporting polypeptides and organic cation transporter 1 contribute to the cellular uptake of the flavonoid quercetin. Naunyn. Schmiedebergs. Arch. Pharmacol., 2014, 387, 883-891.
86. Pashevin, D. A.; Tumanovska, L. V.; Dosenko, V. E.: Nagibin, V. S.; Gurianova, V. L.; Moibenko, A. A.Antiatherogenic effect of quercetin is mediated by proteasome inhibition in the aorta and circulating leukocytes. Pharmacol. Rep., 2011, 63,1009-1018.
87. Moon, J.; Lee, S. M.; Do, H. J.; Cho, Y.; Chung, J. H.; Shin, M. J. Quercetin up-regulates LDL receptor expression in HepG2 cells. Phytother. Res., 2012, 26, 1688-1694.
88. Lee, S. M.; Moon, J.; Chung, J. H.; Cha, Y. J.; Shin, M. J. Effect of quercetin-rich onion peel extracts on arterial thrombosis in rats. Food. Chem. Toxicol., 2013, 57, 99-105.
89. Tang, L.; Peng, Y.; Xu, T.; Yi, X.; Liu, Y.; Luo, Y.; Yin, D.; He, M. The effects of quercetin protect cardiomyocytes from A/R injury is related to its capability to increasing expression and activity of PKCε protein. Mol. Cell. Biochem., 2013, 382,145-152.
90. Haas, M. J.; Onstead-Haas, L. M.; Szafran-Swietlik, A.; Kojanian, H.; Davis, T.; Armstrong, P.; Wong, N. C.; Mooradian, A. D. Induction of hepatic apolipoprotein A-I gene expression by the isoflavonesquercetin and isoquercetrin. Life Sci., 2014, 110, 8-14.
91. Parichatikanond, W.; Pinthong, D.; Mangmool, S. Blockade of the renin-angiotensin system with delphinidin, cyanin, and quercetin. Planta Med., 2012, 78, 1626-1632.
92. Žižkova, P.; Blaškovič, D.; Majekova, M.; Švorc, L.; Račkova, L.; Ratkovska, L.; Veverka, M.; Horakova, L. Novel quercetin derivatives in treatment of peroxynitrite-oxidized SERCA1. Mol. Cell. Biochem., 2014, 386, 1-14.
93. Baran, I.; Ganea, C. RyR3 in situ regulation by Ca(2+) and quercetin and the RyR3-mediated Ca(2+) release flux in intact Jurkat cells. Arch. Biochem. Biophys., 2013, 540, 145-159.
94. Harwood M.; Danielewska-Nikiel B.; Borzelleca J.F.; Flamm G.W.; Williams G.M.; Lines T.C. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem. Toxicol., 2007, 45, 2179-205.
95. Ossola B.; Kaariainen T.M.; Mannisto P.T. The multiple faces of quercetin in neuroprotection. Expert. Opin. Drug Saf., 2009, 8, 397-409.
96. Zhao, L.; Wu, J.; Wang, Y.; Yang, J.; Wei, J.; Gao, W.; Guo, C. Cholesterol metabolism is modulated by quercetin in rats. J Agric. Food Chem., 2011, 59, 1104-1108.